치료저항성 조현병에서 클로자핀 치료의 현황

참고문헌 (49)

1. Jung Suk Lee, "Korean Medication Algorithm for Schizophrenia 2019, Second Revision: Treatment of Psychotic Symptoms", Clinical Psychopharmacology and Neuroscience, 18(3), pp.386~394 (2020), 대한정신약물학회[DOI]
2. Taylor DM, "Clozapine for Treatment-Resistant Schizophrenia : Still the Gold Standard", CNS Drugs, 31, pp.177~180 (2017)
3. Ban TA, "Fifty years chlorpromazine : a historical perspective", Neu-ropsychiatr Dis Treat, 3, pp.495~500 (2007)
4. Kuhn R, "The treatment of depressive states with G 22355(imipra-mine hydrochloride)", Am J Psychiatry, 115, pp.459~464 (1958)
5. Crilly J, "The history of clozapine and its emergence in the US mar-ket : a review and analysis", Hist Psychiatry, 18, pp.39~60 (2007)
6. Hippius H, "A historical perspective of clozapine", J Clin Psychiatry, 60(Suppl 12), pp.22~23 (1999)
7. 이건석, "치료저항성 조현병: 정의와 임상양상", 대한조현병학회지, 23(2), pp.45~50 (2020), 대한조현병학회[DOI]
8. Kane J, "Clozapine for the treat-ment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)
9. Wahlbeck K, "Evidence of clozap-ine’s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials", Am J Psychiatry, 156, pp.990~999 (1999)
10. Lewis S, "CATIE and CUtLASS : can we handle the truth", Br J Psychiatry, 192, pp.161~163 (2008)
11. McEvoy JP, "Effectiveness of clozapine versus olanzap-ine, quetiapine, and risperidone in patients with chronic schizo-phrenia who did not respond to prior atypical antipsychotic treat-ment", Am J Psychiatry, 163, pp.600~610 (2006)
12. Samara MT, "Efficacy, acceptability, and tolerability of antipsy-chotics in treatment-resistant schizophrenia: a network meta-anal-ysis", JAMA Psychiatry, 73, pp.199~210 (2016)
13. Siskind D, "Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis", Br J Psychia-try, 209, pp.385~392 (2016)
14. Huhn M, "Comparative efficacy and tolerability of 32oral antipsychotics for the acute treatment of adults with multi-epi-sode schizophrenia: a systematic review and network meta-analy-sis", Lancet, 394, pp.939~951 (2019)
15. Möller HJ, "Negative symptoms in schizophrenia: considerations for clinical trials", Psychopharmacology, 115, pp.221~228 (1994)
16. Bilder RM, "Neurocognitive effects of clozapine, olanzapine, ris-peridone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder", Am J Psychiatry, 159, pp.1018~1028 (2002)
17. Han M, "Cog-nitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics", Int Clin Psycho-pharmacol, 30, pp.89~95 (2015)
18. Campana M, "Character-istics and definitions of ultra-treatment-resistant schizophrenia—a systematic review and meta-analysis", Schizophr Res, 228, pp.218~226 (2021)
19. Mouaffak F, "Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia", Clin Neurophar-macol, 29, pp.28~33 (2006)
20. Hasan A, "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance", World J Biol Psychiatry, 13, pp.318~378 (2012)
21. Howes OD, "Treatment-Resistant Schizophrenia:Treatment Response and Resistance in Psychosis (TRRIP) Work-ing Group Consensus Guidelines on Diagnosis and Terminology", Am J Psychiatry, 174, pp.216~229 (2017)
22. Kreyenbuhl J, "The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommen-dations 2009", Schizophr Bull, 36, pp.94~103 (2010)
23. Remington G, "Guidelines for the pharmacotherapy of schizophrenia in adults", Can J Psychiatry, 62, pp.604~616 (2017)
24. Sherwood M, "A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine", J Psychopharmacol, 26, pp.1175~1184 (2012)
25. Subramaniam M, "Metabolic differences between Asian and Caucasian pa-tients on clozapine treatment", Hum Psychopharmacol, 22, pp.217~222 (2007)
26. 김철응, "한국 성인 정신분열병 환자의 평균 클로자핀 사용량과 혈중농도에 관한 연구", 신경정신의학, 40(1), pp.109~117 (2001), 대한신경정신의학회
27. Lee ST, "Determination of phar-macokinetic properties of clozapine and norclozapine in Korean schizophrenia patients", Int Clin Psychopharmacol, 24, pp.139~144 (2009)
28. Kontaxakis VP, "Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review", Eur Psychiatry, 20, pp.409~415 (2005)
29. Berk M, "Monitoring the safe use of clozapine: a consensus view from Victoria, Australia", CNS Drugs, 21, pp.117~127 (2007)
30. Bartoli F, "Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine:a meta-analysis", J Psychiatr Res, 108, pp.24~33 (2019)
31. Siskind DJ, "Augmentation strategies for clozapine refractory schizophre-nia: A systematic review and meta-analysis", Aust N Z J Psychiatry, 52, pp.751~767 (2018)
32. Taylor DM, "Augmentation of clozap-ine with a second antipsychotic a meta-analysis", Acta Psychiatr Scand, 125, pp.15~24 (2012)
33. Galling B, "Antipsychotic augmentation vs. monotherapy in schizophre-nia: systematic review, meta-analysis and meta-regression analy-sis", World Psychiatry, 16, pp.77~89 (2017)
34. Wenthur CJ, "Classics in chemical neuroscience: clo-zapine", ACS Chem Neurosci, 4, pp.1018~1025 (2013)
35. Cipriani A, "Aripiprazole versus haloperidol in combination with clo-zapine for treatment-resistant schizophrenia: a 12-month, random-ized, naturalistic trial", J Clin Psychopharmacol, 33, pp.533~537 (2013)
36. Shiloh R, "Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study", Br J Psychiatry, 171, pp.569~573 (1997)
37. Tiihonen J, "Association of antipsychotic polypharmacy vs mono-therapy with psychiatric rehospitalization among adults with schizo-phrenia", JAMA Psychiatry, 76, pp.499~507 (2019)
38. Mossaheb N, "Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine", World J Biol Psychiatry, 11, pp.502~505 (2010)
39. Chang JS, "Aripiprazole augmentation in clozapine-treated patients with re-fractory schizophrenia: an 8-week, randomized, double-blind, pla-cebo-controlled trial", J Clin Psychiatry, 69, pp.720~731 (2008)
40. Chang JS, "The sustained effects of ar-ipiprazole-augmented clozapine treatment on the psychotic symp-toms and metabolic profiles of patients with refractory schizophre-nia", J Clin Psychopharmacol, 32, pp.282~284 (2012)
41. Bogers JP, "Clozapine underutilization in the treatment of schizophrenia: how can clo-zapine prescription rates be improved?", J Clin Psychopharmacol, 36, pp.109~111 (2016)
42. Stroup TS, "Geographic and clinical variation in clozapine use in the United States", Psychi-atr Serv, 65, pp.186~192 (2014)
43. Bachmann CJ, "International trends in clozapine use: a study in 17 countries", Acta Psychiatr Scand, 136, pp.37~51 (2017)
44. Alvir JM, "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States", N Engl J Med, 329, pp.162~167 (1993)
45. Bastiampillai T, "Changes for clozap-ine monitoring in the United States", Mol Psychiatry, 21, pp.858~860 (2016)
46. Kang BJ, "Long-term patient monitoring for clozapine-induced agranulocytosis and neutrope-nia in Korea: when is it safe to discontinue CPMS?", Hum Psycho-pharmacol, 21, pp.387~391 (2006)
47. Schulte PF, "A Dutch guideline for the use of clozapine", Aust N Z J Psychiatry, 44, pp.1055~1056 (2010)
48. Chandrasekaran PK, "Agranulocytosis monitoring with clozapine patients: to follow guidelines or to attempt therapeutic controver-sies?", Singapore Med J, 49, pp.96~99 (2008)
49. Nielsen J, "Worldwide differences in regulations of clozapine use", CNS Drugs, 30, pp.149~161 (2016)

관련 논문AI추천